<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35472029</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2379-3708</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>JCI insight</Title>
          <ISOAbbreviation>JCI Insight</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Loss of voltage-gated hydrogen channel 1 expression reveals heterogeneous metabolic adaptation to intracellular acidification by T cells.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e147814</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1172/jci.insight.147814</ELocationID>
        <Abstract>
          <AbstractText>Voltage-gated hydrogen channel 1 (Hvcn1) is a voltage-gated proton channel, which reduces cytosol acidification and facilitates the production of ROS. The increased expression of this channel in some cancers has led to proposing Hvcn1 antagonists as potential therapeutics. While its role in most leukocytes has been studied in depth, the function of Hvcn1 in T cells remains poorly defined. We show that Hvcn1 plays a nonredundant role in protecting naive T cells from intracellular acidification during priming. Despite sharing overall functional impairment in vivo and in vitro, Hvcn1-deficient CD4+ and CD8+ T cells display profound differences during the transition from naive to primed T cells, including in the preservation of T cell receptor (TCR) signaling, cellular division, and death. These selective features result, at least in part, from a substantially different metabolic response to intracellular acidification associated with priming. While Hvcn1-deficient naive CD4+ T cells reprogram to rescue the glycolytic pathway, naive CD8+ T cells, which express high levels of this channel in the mitochondria, respond by metabolically compensating mitochondrial dysfunction, at least in part via AMPK activation. These observations imply heterogeneity between adaptation of naive CD4+ and CD8+ T cells to intracellular acidification during activation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Coe</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom. Research Institute, Queen Mary University of London, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Inflammation and Therapeutic Innovation, Queen Mary University of London, Charterhouse Square, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Poobalasingam</LastName>
            <ForeName>Thanushiyan</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom. Research Institute, Queen Mary University of London, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Inflammation and Therapeutic Innovation, Queen Mary University of London, Charterhouse Square, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fu</LastName>
            <ForeName>Hongmei</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom. Research Institute, Queen Mary University of London, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Inflammation and Therapeutic Innovation, Queen Mary University of London, Charterhouse Square, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bonacina</LastName>
            <ForeName>Fabrizia</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Guosu</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom. Research Institute, Queen Mary University of London, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Inflammation and Therapeutic Innovation, Queen Mary University of London, Charterhouse Square, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morales</LastName>
            <ForeName>Valle</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moregola</LastName>
            <ForeName>Annalisa</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mitro</LastName>
            <ForeName>Nico</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheung</LastName>
            <ForeName>Kenneth Cp</ForeName>
            <Initials>KC</Initials>
            <AffiliationInfo>
              <Affiliation>William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom. Research Institute, Queen Mary University of London, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Inflammation and Therapeutic Innovation, Queen Mary University of London, Charterhouse Square, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ward</LastName>
            <ForeName>Eleanor J</ForeName>
            <Initials>EJ</Initials>
            <AffiliationInfo>
              <Affiliation>William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom. Research Institute, Queen Mary University of London, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Inflammation and Therapeutic Innovation, Queen Mary University of London, Charterhouse Square, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nadkarni</LastName>
            <ForeName>Suchita</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom. Research Institute, Queen Mary University of London, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Inflammation and Therapeutic Innovation, Queen Mary University of London, Charterhouse Square, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aksentijevic</LastName>
            <ForeName>Dunja</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom. Research Institute, Queen Mary University of London, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bianchi</LastName>
            <ForeName>Katiuscia</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Norata</LastName>
            <ForeName>Giuseppe Danilo</ForeName>
            <Initials>GD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Capasso</LastName>
            <ForeName>Melania</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, Bonn, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marelli-Berg</LastName>
            <ForeName>Federica M</ForeName>
            <Initials>FM</Initials>
            <AffiliationInfo>
              <Affiliation>William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom. Research Institute, Queen Mary University of London, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Inflammation and Therapeutic Innovation, Queen Mary University of London, Charterhouse Square, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Neurodegenerative Diseases (DZNE) within the Helmholtz Association, Bonn, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>CH/15/2/32064</GrantID>
            <Acronym>BHF_</Acronym>
            <Agency>British Heart Foundation</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>PG/14/84/31136</GrantID>
            <Acronym>BHF_</Acronym>
            <Agency>British Heart Foundation</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>JCI Insight</MedlineTA>
        <NlmUniqueID>101676073</NlmUniqueID>
        <ISSNLinking>2379-3708</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011522">Protons</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7YNJ3PO35Z</RegistryNumber>
          <NameOfSubstance UI="D006859">Hydrogen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006859" MajorTopicYN="Y">Hydrogen</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011522" MajorTopicYN="Y">Protons</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Adaptive immunity</Keyword>
        <Keyword MajorTopicYN="N">Immunology</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>17</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35472029</ArticleId>
        <ArticleId IdType="doi">10.1172/jci.insight.147814</ArticleId>
        <ArticleId IdType="pii">147814</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
